TOKYO, Jan 10 (Reuters) - Japan's Takeda Pharmaceutical Co Ltd expects annual sales from new lung cancer drug brigatinib, added to its portfolio with the acquisition of Ariad Pharmaceuticals Inc, will exceed $1 billion, the Japanese company's CEO said on Tuesday.

"It has the potential to be the best in class," Christophe Weber said during a conference after Takeda announced the $5.2 billion acquisition of Ariad in a bid to boost its oncology pipeline.

(Reporting by Tim Kelly; Editing by Michael Perry)